GrowBLOX Sciences, Inc. CEO Craig Ellins to Participate as a Panelist at Renowned 2014 Milken Institute Global Conference

LAS VEGAS, April 30, 2014 /PRNewswire/ -- GrowBLOX Sciences, Inc. (OTCQB: GBLX) CEO, Craig Ellins, will be participating on a panel of thought provoking industry leaders in the medicinal marijuana sector at the Milken Institute Global Conference.  The Milken Conference is a prominent forum where investors from around the world, industry and government leaders, experts and economists from diverse industries analyze a myriad of issues facing global markets.  The conference aligns decision-makers from private and public sectors in order to debate and discuss practical solutions for prosperity and action around the globe.

This distinctive panel will focus on the legalization and social implications that surround the legal marijuana industry, as well as the vast business opportunities that are available in today's marketplace.  While the industry historically has had a negative stigma attached to it – being until recently an underground market – medicinal marijuana, now legal in 21 states, is projected to become a $6 billion industry by 2016.

The panel discussion: "The Highs – and Lows – of the Cannabis Economy," will take place today, April 30, 2014 and will be moderated by Mike 'Zappy' Zapolin. Zappy is a social entrepreneur recognized as one of the key industry leaders in the cannabis economy.  His company, Zappy Inc., is focused on the life sciences opportunities, including new medical applications and safe delivery.  Other co-panelists include DigiPath CEO, Todd Denkin, WeedMD RX Chairman, Michael Kraft, National Families in Action Inc. CEO, Sue Rusche, and Goodwin Procter LLP legal expert, Doug Praw.

Ellins will provide details on the Company's proprietary growing technology at the conference.  The GrowBLOX controlled environment agricultural chambers are designed to create a consistent environment for each plant by controlling the light, humidity, nutrition, temperature and aeration, while excluding outside stresses like, pathogens and pests.  All parameters are pre-programmed for each unit and optimized for each cultivar, ensuring the composition and yield from each batch will consistently reflect the genetic makeup of the plants.  The GrowBLOX cultivation method will make it possible to reliably provide products with very defined properties to patients with specific needs.  

For more information surrounding the proprietary growing technology, please visit http://www.gbsciences.com.

For more information on the Milken Institute Global Conference, please visit http://www.globalconference.org/.  

About GrowBLOX Sciences, Inc.

GrowBLOX Sciences, Inc., is a research and biotechnical company that has developed proprietary indoor growing chambers specifically designed for medical cannabis cultivation.  The GrowBLOX chamber allows for completely controlled growing conditions, ensuring the manufacture of a consistent, toxin-free, natural and medicinal-grade product.  The Company believes that the advantages of a controlled environment over traditional outdoor or greenhouse growing, will empower the public, nutraceutical and pharmaceutical industries to embrace cannabis as an effective treatment for a myriad of serious medical conditions.  http://www.gbsciences.com

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results.  Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Craig Ellins
CEO, GrowBLOX Sciences, Inc.
+1-844-843-BLOX ext. 01

SOURCE GrowBLOX Sciences, Inc.